Filtered By:
Infectious Disease: Fungal Infections

This page shows you your search results in order of date.

Order by Relevance | Date

Total 83 results found since Jan 2013.

Cerebral fungal infections as a cause of stroke in cardiac surgery patients: Be Cautious!!
Neurological dysfunction in the postoperative period following cardiac surgery is most commonly attributed to thromboembolism or an intracranial bleed. Fungal infection is a rare cause of cerebral infarction and hemiparesis in an otherwise healthy patient. Cerebral Aspergillus infections are common in immunocompromised patients and is not considered as the first-line differential diagnosis of cerebral infarcts in a cardiac surgery patient. The infection is usually a secondary from lung, paranasal sinuses, or heart and forms microthrombi in large or medium sized cerebral vessels.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 30, 2023 Category: Anesthesiology Authors: Avneet Singh, Arushi Goyal, Manpreet Singh, Sidharth Garg, Sandeep Moudgil, Vipin Gupta Tags: Letter to the Editor Source Type: research

Characteristics and Outcomes of Candidemia in Patients with Durable Left Ventricular Assist Device Support
In conclusion, fungemia is a rare and severe complication in LVAD patients occurring early postimplant.
Source: ASAIO Journal - August 1, 2022 Category: Medical Devices Tags: Adult Circulatory Support Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Recurrent Stroke and Fatal Ruptured Mycotic Aneurysm Caused by Invasive < em > Aspergillus fumigatus < /em > Infection
CONCLUSION: In immunosuppressed patients with neutropenia or using chronic steroids who have concurrent pulmonary and CNS infection, there should be a low threshold to treat empirically for fungal infections prior to confirmation of diagnosis.PMID:33974773
Source: WMJ - May 11, 2021 Category: General Medicine Authors: Istiaq Mian Sam Ives Garry Jean-Louis Andrew Laczniak Source Type: research